Yes, you are correct that the DCVax trial did require more than a simple biopsy to be eligible for the trial. However, your statement that
DCVax-L's screen requiring total resection
is not accurate.
There were patients enrolled in the DCVax-L trial who had significant residual disease remaining after their surgery, and their survival was better than those patients with significant residual disease in the ECA. The following is a slide from the May 10, 2022 NYAS presentation.
Market Data 
Markets 
AI
